ERBB2 and breast carcinoma: We have previously shown that high calpain-2 expression is associated with worse prognosis in patients with basal-like or triple-negative diseases [23] and that calpain-1 expression is associated with trastuzumab response in HER2+ breast cancer patients [27, 33].